We examined the effect of liver X receptor (LXR) agonists on vascular calcification, prevalent in atherosclerotic lesions. T0901317, an LXR agonist, augmented protein kinase A (PKA)-induced mineralization and alkaline phosphatase (ALP) activity in aortic smooth muscle cells isolated from wildtype, but not from Lxrb À/À mice. A six-hour T0901317 treatment augmented the PKA-induced expression of the phosphate transporter Pit-1, a positive regulator of mineralization, suggesting a direct role. A ten-day T0901317 treatment attenuated PKA-induced expression of mineralization inhibitors, osteopontin and ectonucleotide pyrophosphatase/phosphodiesterase-1, suggesting an indirect role. The effects of T0901317 were attenuated by inhibition of ALP, Pit-1 and Rho-associated kinase, but not by inhibition of PKA. These results suggest that T0901317-augmented mineralization occurs downstream of PKA, involving both direct and indirect LXR-mediated pathways.
Introduction
Liver X receptor (LXR), the nuclear hormone receptor, plays a crucial role in cholesterol homeostasis. LXR activates expression of genes involved in cholesterol efflux, such as ABCA1, and reduces cytokine-induced gene expression [1, 2] . In mice, synthetic LXR agonists reduce atherosclerosis, while LXR deficient hyperlipidemic mice have accelerated atherosclerosis [3] [4] [5] . LXRa is expressed primarily in the liver, intestines, adipose tissue, adrenal glands, lungs, and kidneys, whereas LXRb is expressed ubiquitously and is likely to mediate any direct effects on vascular cells. We and others have found that oxysterols, now known to be physiological ligands of LXR [6] , stimulate matrix mineralization in vascular cells [7, 8] . However, the effect of synthetic LXR agonists on vascular cell calcification is not known.
Vascular calcification, highly prevalent in atherosclerosis, as well as in diabetes and chronic kidney disease [9] , is increasingly being used as a surrogate marker for atherosclerosis. Its presence is associated with a poor prognosis, specifically a greater likelihood of cardiovascular events such as myocardial infarction, stroke, and death [10] . Vascular calcification is promoted by monocyte-macrophages and inflammatory cytokines commonly present in atherosclerotic plaques [11] [12] [13] .
Under physiological conditions, vascular calcification is constitutively suppressed by local factors in the extracellular milieu [14, 15] . Extracellular pyrophosphate (PPi) is generated from cleavage of nucleotide triphosphates by ectonucleotide pyrophosphatase/phosphodiesterase-1 (Enpp1/Npp1/ PC-1). Absence of this enzyme leads to a congenital, lifethreatening vascular calcification in humans [16] . Additionally, in vitro studies showed that osteopontin (OPN), an extracellular structural protein, also negatively regulates vascular calcification [17] . In contrast, vascular calcification is stimulated by increased phosphate levels and increased alkaline phosphatase (ALP) activity. High phosphate acts, at least in part, through Pit-1, a type III sodium-dependent phosphate cotransporter [18, 19] . Terkeltaub and colleagues showed that the primary in vivo role of ALP is to cleave the mineralization inhibitor, PPi [20] .
We previously established an in vitro model of PKA-induced vascular cell calcification [21, 22] . This model has a physiological basis since PKA is a mediator of parathyroid hormone (PTH), which when chronically elevated leads to aortic calcification in rodent models [23] and is associated with increased atherosclerotic calcification in patients with end-stage renal disease [24] . In the present study, we tested the effects of LXR agonists on this in vitro PKA-induced calcification model in primary aortic cells isolated from wild-type (WT) and Lxrb À/À mice. 2. Materials and methods
Materials
Forskolin was from Calbiochem, T0901317 and Y27632 from Cayman Chemical, and GW3965, 25-hydroxycholesterol (25-OH), and phosphonoformic acid from Sigma-Aldrich.
Cell culture
Vascular cells (passages [4] [5] [6] [7] [8] were isolated from the thoracic aorta of mice [25] . Lxrb À/À mice were a gift of Dr. David Mangelsdorf (UT Southwestern). The cells were immunoreactive for smooth muscle a-actin, (Dako Corp.) but not for endothelial markers (von Willebrand factor, Dako Corp.). Cells were treated at confluence with the indicated reagents in a-minimal essential medium (a-MEM) supplemented with 10% fetal bovine serum and 5 mM b-glycerophosphate (Sigma). Media were replaced with fresh agents every 3-4 days.
Mineral incorporation
Matrix calcium levels (normalized to total protein) were analyzed by the o-cresolphthalein complexone method (Teco Diagnostics) in quintuplicate [21] .
Alkaline phosphatase activity
ALP activity (normalized to total protein) was assessed colorimetrically and assayed in quintuplicate [21] .
Gene expression
Realtime RT-qPCR was performed using 1-step qRT-PCR (Biochain Institute Inc.) in the Mx3005P (Stratagene). Primer sequences are indicated previously [21] , except for ABCA1 -(sense) CGTGTGAGCAAAGCCAAG, (antisense) AAGATGATAATGACCAGTG-TAGC; LXRa -(sense) TACAACCGGGAAGACTTTGC, (antisense) TGCAGAGAAGATGCTGATGG; and LXRb -(sense) CAG-GAGATTGTGGACTTTGC, (antisense) TTGTAGCGTCTGGCTGTTTC. bActin was used as a normalizing gene.
Data analysis
Each experiment was performed in Ptriplicate wells and repeated Pthree times. Data are expressed as the means ± S.E.M. Means were compared using one-way ANOVA, with comparison of different groups by Fisher's protected least significant difference test. A value of P 6 0.05 was considered significant.
Results

LXR isotype expression
The level of LXRa expression is similar in aortic cells from WT and Lxrb À/À cells, whereas LXRb is reduced by 95% in the Lxrb À/À cells (Fig. 1A) . The residual Lxrb transcript detected in the Lxrb À/À cells does not encode a functional protein (data not shown). Consistent with this expression profile, T0901317 upregulated expression of ABCA1, a known LXR target, by 10-fold in WT cells but only 2-fold in Lxrb À/À cells (Fig. 1B) .
Matrix mineralization
Treatment with the PKA activator forskolin (Fsk) for 10 days significantly increased matrix mineralization (Fig. 2A) . T0901317 alone had no significant effect, whereas cotreatment with T0901317 augmented Fsk-induced mineralization ( Fig. 2A) . This effect was not observed in Lxrb À/À cells ( Fig. 2A) . Other known LXR agonists, GW3965 and 25-OH, also augmented the Fsk-induced mineralization ( Fig. 2A and B) . Consistent with previous results [8] , and in contrast to the synthetic LXR agonists, 25-OH alone enhanced mineral incorporation, suggesting that 25-OH has effects independent of LXR activation.
Next, we examined the effects of LXR agonists on regulators of mineralization. Cotreatment with either T0901317 or GW3965 augmented the Fsk-induced ALP activity in WT (Fig. 2C) but not in Lxrb À/À cells (Fig. 2D) . Treatment with Fsk for 6 h induced Pit-1 mRNA in both WT and Lxrb À/À cells (Fig. 3A) . Cotreatment with T0901317 significantly augmented Fsk-induced Pit-1 expression in WT, but not in Lxrb À/À cells (Fig. 3A) . At this time point, T0901317 did not alter Fsk-induced expression of osteopontin (OPN) and Enpp1 ( Fig. 3B and C) . However, longer (10 days) T0901317 treatment attenuated Fsk-induced expression of both Enpp1 and OPN in WT ( Fig. 3B and C) , but not in Lxrb À/À cells (data not shown), suggesting an indirect regulation by T0901317.
ALP and Pit-1 inhibition
To determine whether inhibition of ALP and Pit-1 attenuates the effects of T0901317, we used their respective inhibitors, levamisole (Lev) and phosphonoformic acid (PFA). Cotreatment with Lev inhibited both Fsk-and Fsk/T0901317-induced matrix mineralization (Fig. 4A) . Similarly, cotreatment with PFA inhibited the effects of T0901317 (Fig. 4B) .
Intracellular signaling
An inhibitor of PKA, H89, was used to assess whether the effects of T0901317 were upstream or downstream of PKA. In the pres- ence of H89, T0901317 was still able to augment mineralization (Fig. 5A , compare Fsk + H89 to Fsk + T0 + H89), suggesting that T0901317 acts downstream of PKA. Since Rho-associated kinase (ROCK-II) has been shown to mediate the calcifying effects of 7-ketocholesterol [7] , we next examined its role in T0901317-in- duced mineralization. Y27632, a ROCK-II inhibitor, partially inhibited Fsk-induced calcification and completely attenuated Fsk/ T0901317-induced mineralization (Fig. 5B ).
Discussion
Given that LXR agonists have anti-atherogenic effects and that calcification is highly prevalent in atherosclerotic plaques, we investigated the effects of synthetic LXR agonists on vascular cell mineralization using synthetic LXR agonists in aortic cells isolated from WT and Lxrb À/À mice. Results showed that although LXR agonists alone had no significant effect, they augmented PKA-induced mineralization in WT cells. The effect appears to be LXRb-dependent, since it is not seen in Lxrb À/À cells.
Results suggest that LXR agonists augmented Fsk-induced mineralization by enhancing positive regulators of mineralization, such as ALP activity and, possibly, Pit-1 and/or by attenuating inhibitors of mineralization, OPN and Enpp1, as depicted in Fig. 5C . Interestingly, the role of Enpp1 is complex since excess Enpp1 can also promote calcification by providing a substrate for ALP [26] . Indeed, this may explain how Fsk can induce calcification despite its induction of Enpp1. Short-term regulation of Pit-1 induction by T0901317 suggests a direct, genomic effect of LXR, whereas inhibition of OPN and Enpp1 required longer treatment, suggesting an indirect mechanism. Results also suggest that T0901317 action occurs downstream of PKA and may be mediated by ROCK-II, which regulates myofibroblast differentiation, extracellular matrix production [27] and matrix mineralization induced by 7-ketocholesterol [7] . ROCK-II also appears to contribute to PKA-mediated calcification itself since Fsk-induced mineralization was partially blocked by Y27632.
Evidence suggests that high phosphate levels induce matrix mineralization by vascular smooth muscle cells via Pit-1 [17, 28] . Pit-1 is also a downstream effector for other mineralization factors, including BMP-2 [29] . In the present study, Fsk-induced Pit-1 expression was augmented by short-term treatment with T0901317, suggesting transcriptional regulation. Indeed, two putative LXR response elements are located in the promoter region of Pit-1, and studies of their functional role are underway. In our results, the attenuation of matrix mineralization by PFA, which inhibits Pit-1 [29] [30] [31] , suggests a role of Pit-1 induction in effects of LXR agonists. However, since PFA is also a PPi analog, it is also possible that PFA inhibition is through this alternative mechanism rather than through Pit-1. Further studies are required to discern whether Pit-1 has a role in the LXR agonist effects.
Chronic inflammation, responsible for atherogenesis, also induces vascular cell calcification [11] [12] [13] , suggesting that similar pathways may regulate both pathogenic processes. Since LXR activation attenuates inflammation, it is less likely that LXR poses adverse effects in arteries lacking atherosclerosis. However, our findings suggest that LXR activation could adversely affect arteries exposed to other pathological factors such as high phosphate and increased PTH signaling seen in end-stage renal patients with hyperparathyroidism. 
